共 17 条
[1]
Structur almechani smforSTI-5 71inhibiti onofAbels ontyrosi nekinase. SchindlerT,BornmannW,Pellicena P,etal. Science . 2000
[2]
Dose escalation of Imatinib mesylate can overcome resistance to standard-dose thera-py in patients with chronic myelogenous leukemia. Kantarjian HM.Talpaz M,O’Brien S,et al. Blood . 2003
[3]
Leukemia[P]. 英国专利:GB0221802D0,2002-10-30
[4]
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Gorre ME,Mohammed M,Ellwood K,et al. Science . 2001
[5]
Role of alpha acidglycoprotein in the in vivo resistance of humanBCR-ABL(+) leukemic cellsto theAbl inhibitorSTI-571. Gambacorti-PasseriniC,BarniR,leCoutreP,et al. J NatlCancerInst . 2000
[6]
Intracranial inhibition of platelet-de-rived growth factor-mediated glioblastoma cell growth by an orally activekinase inhibitor of the2-phenylaminopyrimidine class. KilicK,AlbertaJA,ZdunekPR,et al. Cancer Research . 2000
[7]
The selective tyrosine kinase inhibi-torSTI-571 inhibits small cell lung cancer growth. KrystalGW,HonsawekS,LitzJ,et al. ClinCancerRes . 2000
[8]
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Demetri GD,von Mehren M,Blanke CD, et al. The New England Journal of Medicine . 2002
[9]
Effect of the tyrosine kinaseinhibitorSTI-571 in a patient with a metastatic gastrointestinal stromal tumor. JoensuuH,RobertsPJ,RikalaMS,et al. The New England Journal of Medicine . 2001
[10]
Treatment of chronic myelog-enous leukemia with the tyrosine kinase inhibitorSTI571 results in markedregression of bone marrow fibrosis. Beham-SchmidC,ApfelbeckU,SillH,et al. Blood . 2002